ENFERMEDADES AUTOINMUNES
Hospital Universitario San Cecilio
Granada, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario San Cecilio (13)
2023
-
Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study
Clinical and experimental rheumatology, Vol. 41, Núm. 10, pp. 2105-2114
2018
-
Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity
Lupus, Vol. 27, Núm. 10, pp. 1718-1722
2017
-
Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE)
Clinical and Experimental Rheumatology, Vol. 35, pp. S40-S47
-
New insights into the genetic component of non-infectious uveitis through an Immunochip strategy
Journal of Medical Genetics, Vol. 54, Núm. 1, pp. 38-46
2016
-
First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort
Lupus Science and Medicine, Vol. 3, Núm. 1
-
Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies
Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399
-
Off-label use of rituximab for systemic lupus erythematosus in Europe
Lupus Science and Medicine, Vol. 3, Núm. 1
-
Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus
Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472
2015
-
Specific association of IL17A genetic variants with panuveitis
British Journal of Ophthalmology, Vol. 99, Núm. 4, pp. 566-570
-
Study of association of CTLA4 gene variants to non-anterior uveitis
Tissue Antigens, Vol. 86, Núm. 5, pp. 373-376
2012
-
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts
Autoimmunity Reviews, Vol. 11, Núm. 5, pp. 357-364
2011
2010
-
Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases
Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476